Two doses per year could reshape HIV prevention, but price and licensing issues may limit scalability within the Brazilian public health system (SUS). The “quasi-vaccine” developed by Gilead Sciences arrives in Brazil with rare clinical evidence and global regulatory endorsement. But the geopolitics of voluntary licenses and the pricing logic in rich markets create a dilemma: how to remunerate innovation without turning prevention into a luxury incompatible with universality

How the global shift in health innovation redefines the role of industrial policies and exposes the backwardness of Brazil's strategy The pharmaceutical industry is experiencing a historic shift. The model that, for half a century, concentrated drug discovery in large, integrated corporations is fragmenting. Vertical integration, a symbol of strength in the 20th century, has given way to a decentralized network of small biotechs , academic laboratories, and deep tech startup

How to revive the cooperative model that can transform Brazil into a biotechnology powerhouse When I received the invitation in 2005 to...

The global pharmaceutical and biotechnology industry is experiencing a period of accelerated growth in drug use and spending, driven by...

In June 2025, the US Food and Drug Administration approved a new HIV pre-exposure prophylaxis (PrEP) regimen: the long-acting injectable...

In recent years, I’ve had the privilege of closely following the birth and growth of dozens of health startups, both in Brazil and...

Technological innovation is a fundamental factor for a country’s economic development and competitiveness. In Brazil, intellectual...

In the contemporary global landscape, the concept of an isolated national economy has become a fiction. Nations do not compete solely for...

Health innovation and the remarkable growth of the pharmaceutical sector—with a projected global revenue of USD 1.155 trillion in...